DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Depression - Pipeline Review, H2 2016" report to their offering.
Depression pipeline therapeutics constitutes close to 177 molecules. Out of which approximately 153 molecules are developed by Companies and remaining by the Universities/Institutes. Our latest report Depression - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Depression, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. Treatment includes antidepressants, mood stabilizers or antipsychotics.
The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 14, 25, 25, 1, 67, 16 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 15 and 8 molecules, respectively.
Furthermore, this report also reviews of key players involved in therapeutic development for Depression and features dormant and discontinued projects.
Key Topics Covered:
- Introduction
- Depression Overview
- Therapeutics Development
- Pipeline Products for Depression - Overview
- Pipeline Products for Depression - Comparative Analysis
- Depression - Therapeutics under Development by Companies
- Depression - Therapeutics under Investigation by Universities/Institutes
- Depression Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Depression - Products under Development by Companies
- Depression - Products under Investigation by Universities/Institutes
- Depression - Companies Involved in Therapeutics Development
- Addex Therapeutics Ltd
- Aequus Pharmaceuticals Inc.
- Alkermes Plc
- Allergan Plc
- Alvogen Korea Co., Ltd.
- Amorsa Therapeutics Inc.
- Anavex Life Sciences Corp.
- Biogen Inc
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Calico LLC
- Celon Pharma Sp. z o.o.
- GliaCure Inc.
- H. Lundbeck A/S
- Luye Pharma Group Ltd.
- Mapi Pharma Ltd.
- Mapreg S.A.S.
- Meta-IQ ApS
- Methylation Sciences Inc.
- miCure Therapeutics Ltd.
- Mitsubishi Tanabe Pharma Corporation
- Novartis AG
- Otsuka Holdings Co., Ltd.
- Pfizer Inc.
- Pherin Pharmaceuticals, Inc.
- Polleo Pharma Limited
- Protagenic Therapeutics Inc.
- Relmada Therapeutics, Inc.
- Reviva Pharmaceuticals Inc.
- Richter Gedeon Nyrt.
- Saniona AB
- VistaGen Therapeutics, Inc.
- Zhejiang Huahai Pharmaceutical Co., Ltd.
- Zogenix, Inc.
- Zysis Limited
For more information about this report visit http://www.researchandmarkets.com/research/929k33/depression
